SecBot SecBot
SECBOTREPLAY Home › Report › ANIK

ANIK · Anika Therapeutics reported flat Q4 revenue of $30.6M but full-year…

Anika Therapeutics, Inc. · 8-K filed Feb 26, 2026 at 07:18 ET

At the news

MIXEDIMPACT 6/10

8-K filed Feb 26, 2026 at 07:18 ET

Anika Therapeutics reported flat Q4 revenue of $30.6M but full-year 2025 revenue declined 6% to $112.8M, driven by a 17% drop in OEM Channel sales. The company reaffirmed 2026 revenue guidance of $114-122.5M and announced CFO David Colleran's planned departure in May 2026. Despite improved gross margins and strong commercial channel growth, the negative revenue trend and executive departure outweigh positive operational improvements.

  • Q4 2025 revenue: $30.6M (flat YoY), full-year 2025 revenue: $112.8M (down 6% YoY)
  • Commercial Channel revenue grew 22% in Q4 and 15% for full year 2025
  • OEM Channel revenue declined 12% in Q4 and 17% for full year 2025 due to U.S. pricing pressures
  • CFO David Colleran will depart in May 2026 after transition period

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access